Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- 10 APIs/17 Products Including Rituxan Biosimilar Added to NHI Price List on Nov. 29
November 29, 2017
- MHLW Proposes Pricing Support for Startups: Chuikyo
November 28, 2017
- MHLW Unveils Gx Pricing Plans, Wants to Rectify Distortion by Cutting Oral AG Price: Chuikyo
November 28, 2017
- MHLW Panel Backs Approval for AZ’s Olaparib, Benralizumab and More
November 28, 2017
- CEA-Based Price Tweak Likely to Cover Premium Portion, Not Total Price; Price Raise Also Proposed: Chuikyo
November 28, 2017
- MHLW Proposes Expansion of “Essential Drug” Category to Include Crude Drugs, Ointment Bases, Local Dental Anesthetics and More: Chuikyo
November 28, 2017
- MHLW Proposes Tacking Premiums on Total Drug Price under Cost Calculation Formula: Chuikyo
November 27, 2017
- New Price Cut Scheme for Off-Patent Meds Proposed with Mitigation Plans, but Payer Reps Say Gx Transition Too Slow: Chuikyo
November 24, 2017
- Quarterly Market Expansion Re-Pricing Pitched for 35-Plus Billion Yen Products: Chuikyo
November 24, 2017
- MHLW Proposes Post-Launch Foreign Price Adjustments: Chuikyo
November 24, 2017
- Draft Outline of Drug Pricing Overhaul Unveiled at Chuikyo; De-Facto Shrinkage for Price Maintenance Scheme Proposed
November 24, 2017
- Chuikyo Agrees to Define Scope of Off-Year Re-Pricing by 2020-End for 1st Off-Year Revision in April 2021
November 22, 2017
- MHLW Advisory Panel to Review Otsuka’s Schizophrenia Med Brexpiprazole on Dec. 4
November 22, 2017
- In Rare Moves, Parmodia and Istodax to Skip Price Listing for 2nd Time
November 20, 2017
- Health Sciences Council’s Panel Approves Basic Framework for “Guidelines,” “Plans” for COI Management in “Specified Clinical Research”
November 20, 2017
- MHLW Panel to Continue Discussions on Inclusion of Zoster and Trivalent Vaccines in Public Vaccination Programs
November 20, 2017
- LDP Lawmakers Air Concerns over Govt’s Drug Pricing Plans: Social Security Taskforce
November 20, 2017
- Govt Plans to Apply 5 Price Bands for Listed Generics in “Off-Year” Revisions, Maintain 50% Rule for 1st Generics in April
November 20, 2017
- MHLW Panel Members Call for Tougher Regulations on Drug Rep Activities
November 17, 2017
- Annual Re-Pricing Likely to Start in FY2021 for Scope of Products Defined in 2020
November 17, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…